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Low Prevalence of blaOXA-143 in Private Hospitals in Brazil
We read with great interest C. S. Antonio et al.’s letter
describing the high prevalence of Acinetobacter baumannii car-
rying blaOXA-143 in Brazilian hospitals (1). Recently, we carried
out a similar study, and although the blaOXA-143 gene was
identified, its frequency was lower than that reported by An-
tonio et al. (1).
During 2008, a total of 803 Gram-negative bacillus iso-
lates, 1 isolate per patient, were collected from 17 private
hospitals located in eight cities from four distinct geographic
Brazilian regions. Among them, 91 (11.3%) were A. bau-
mannii isolates that were recovered mainly from the respi-
ratory tract (70.3%) and bloodstream (24.2%). Susceptibil-
ity testing was performed by CLSI broth microdilution (3).
The detection of metallo--lactamase (ML)- and carbap-
enem-hydrolyzing class D -lactamase (CHDL)-encoding
genes was performed by multiplex PCR (5, 7, 9) and con-
firmed by sequencing. The presence of the insertion se-
quence ISAba1 upstream of the CHDL-encoding genes was
also investigated. Genetic relatedness among CHDL-pro-
ducing A. baumannii isolates, including the first OXA-23-
producing A. baumannii clone isolated in Brazil (4), was
evaluated by pulsed-field gel electrophoresis (PFGE).
A total of 83/91 (91.2%) isolates were resistant to carbap-
enems. We also observed low rates of susceptibility to ami-
kacin (18.7%), ceftazidime (12.1%), cefepime (8.8%), pip-
eracillin-tazobactam (3.3%), and ciprofloxacin (3.3%). In
contrast, most A. baumannii isolates were susceptible to
polymyxin B (MIC90, 1 g/ml; 97.8% of the isolates were
susceptible).
ML-encoding genes were not identified in our study, as was
also reported by Antonio et al. (1). However, we identified the
blaOXA-23 gene in carbapenem-resistant isolates more fre-
quently than in the former study (83.5% versus 41.7%). The
blaOXA-23 gene was found in all carbapenem-resistant iso-
lates from the cities of Belo Horizonte, Blumenau, Curitiba,
and Sa˜o Luís, followed by Rio de Janeiro (93.7%), Porto
Alegre (80.0%), and Sa˜o Paulo (69.0%). These results are in
accordance with previous local reports (2, 4, 6) that empha-
size that this gene is widespread in our country. The ISAba1
element was positioned upstream of blaOXA-23 in all isolates,
whereas no insertion sequence was observed upstream of
blaOXA-51. Although A. baumannii carrying blaOXA-58 and
blaOXA-72 had recently been described in Brazil (1, 8), no
isolates carrying these variants were found in our study.
Nine distinct PFGE clones were identified among the 76
OXA-23-producing A. baumannii isolates. The predominance
of a single clone (clone A [36.8% of the isolates]) was observed
in isolates collected from six distinct Brazilian cities. This clone
exhibited a PFGE profile similar to that of the first Brazilian
clone producer of OXA-23 (4). A. baumannii belonging to
clones B (17.1%) and D (9.2%) were also identified in isolates
collected from distinct cities, while other genotypes were iden-
tified in specific locations.
While Antonio et al. (1). reported a high prevalence of the
blaOXA-143 gene (58.3%), we found that only 7 of 83 (8.4%) A.
baumannii isolates carried this gene. These isolates were col-
lected from a few hospitals located in the cities of Sa˜o Paulo
(n  6) and Rio de Janeiro (n  1). In both studies, the
majority of OXA-143-producing A. baumannii isolates were
recovered from cities located in Sa˜o Paulo State. However,
while Antonio et al. observed that 70% (21/30) of the iso-
lates from this region carried the blaOXA-143 gene, in the
present study, we identified this resistance determinant in
only 20.7% (6/29) of isolates collected from Sa˜o Paulo.
Moreover, we have observed the predominance of a single
PFGE clone among the seven OXA-143-producing A. bau-
mannii isolates, which contrasts with results obtained by
Antonio et al., in which 7 distinct enterobacterial repetitive
intergenic consensus sequence (ERIC) PCR clones har-
bored the blaOXA-143 gene. Nevertheless, in their study, the
high prevalence of OXA-143-producing isolates could also
be partially justified by the intrahospital spread of a single
clone, which corresponded to 57.1% of all OXA-143-pro-
ducing isolates (1). The high prevalence of blaOXA-23 found
in our study may also be justified by intra- and interhospital
spread of endemic clones. The results of these two studies
show that the prevalence of CHDLs may vary according to
the disseminated clone in a specific hospital or region and
emphasize the importance of appropriate adherence to in-
fection control measures. Thus, wide national surveillance
studies are necessary to analyze the real prevalence of
CHDLs in Brazilian hospitals.
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Authors’ Reply
The foregoing letter by Werneck et al. provides additional
information on the occurrence of carbapenem-hydrolyzing
class D -lactamase (CHDL)-encoding genes among Acineto-
bacter baumannii isolates collected from private hospitals in
Brazil. In the results, the authors reported a lower prevalence
of blaOXA-143 (8.4%) among their study isolates than among
the isolates in our previous report (58.3%), which included
carbapenem-resistant A. baumannii isolates collected from
public hospitals (1). In this regard, there are several factors to
be considered for the apparently discordant results, besides
hospital type. In fact, as mentioned by Werneck et al., in our
study, the high prevalence of OXA-143-producing A. bauman-
nii isolates could partially be justified by the intrahospital
spread of a single clone. Regardless, valuable information in
the letter by Werneck et al. was the identification of OXA-
143-producing A. baumannii in Rio de Janeiro (second-largest
metropolitan area in Brazil after Sa˜o Paulo), which is worri-
some, since, apparently, strains of A. baumannii carrying
blaOXA-143 have been restricted to hospitals located in Sa˜o
Paulo (1). In this regard, the prevalence of CHDLs may also
vary according to specific region. Thus, although data on
OXA-143 are currently few (1, 3), there is supportive evidence
that A. baumannii strains carrying blaOXA-143 genes are spread-
ing in Brazilian hospitals (N. Lincopan et al., unpublished
data).
Surprisingly, like the SPM-1 metallo-beta-lactamase, the
novel OXA-143 enzyme was identified for the first time in
Brazil (3, 4). Currently, SPM-1-producing Pseudomonas aerugi-
nosa strains are endemic to and highly prevalent in Brazilian
hospitals (2). So, for Brazil, the widespread occurrence of
SPM-1 should provide a salutary lesson from which to draw
experience in order to avoid the spread of OXA-143-producing
A. baumannii isolates. The rapid emergence of these isolates
and their potential spread require very close monitoring and
surveillance.
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